Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVT-5873 in pancreatic cancer and CA19-9 positive malignancies
NCT02672917Phase 1Terminated
- Sponsor
- BioNTech SE
- Start
- Jan 2016
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVT-5873 in pancreatic ductal adenocarcinoma (PDAC) and malignant neoplasm (6 arms), sponsored by BioNTech SE. Primary endpoints: Treatment related adverse events, Maximum Tolerated Dose and 1 more. Started Jan 2016; status: terminated.
02
Drugs
MVT-5873
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)malignant neoplasm
Beyond the preview
Go deeper on NCT02672917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672917.